文献速递系统性红斑狼疮

系统性红斑狼疮患者COVID-19调查:417例分析

COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients.
PubMed 文献 · Semin Arthritis Rheum · 2020-06-30

该研究通过匿名问卷在10天内调查了3家转诊中心的417例系统性红斑狼疮(SLE)患者,评估COVID-19影响。发热、嗅觉丧失、干咳、自报神经精神性SLE病史及近期接触确诊COVID-19者与COVID-19关联更强。羟氯喹未见保护作用。

要点

  • 发热、嗅觉丧失、干咳、神经精神性SLE病史及近期接触与COVID-19关联更强。
  • 羟氯喹未显示对感染的直接保护作用,但不能排除其他获益。

核心结论

  • 大多数SLE患者COVID-19患病率可能仅轻度增加,但重症病例信息有限。
  • 羟氯喹似乎不直接保护免于感染,但不能排除其他有益作用。
  • containment policies and behavioural preventive measures could have a major role in limiting the impact of COVID-19 in patients with SLE.

研究设计与样本

  • 通过www.surveymonkey.com在10天内对3家转诊中心的SLE患者发放26项匿名问卷,调查人口学、SLE临床特征、COVID-19诊断及治疗和日常习惯变化。
  • 将调查数据与已发表的一般人群估计值进行比较。

主要发现

  • 417例患者完成调查,超过60%报告有与COVID-19重叠的症状。
  • 发热、嗅觉丧失、干咳、自报神经精神性SLE病史及近期接触确诊COVID-19者与COVID-19关联更强。
  • 患者接触者的症状及对行为预防措施依从性较低也与COVID-19关联更强。
  • 使用羟氯喹的受试者未见保护效应。

临床怎么用

  • 对SLE患者应重视发热、嗅觉丧失、干咳等症状及近期接触史,及时评估COVID-19。
  • 不应将羟氯喹视为COVID-19感染的预防手段。
  • 应加强SLE患者及其接触者的行为预防措施和 containment policies。

局限性

  • 通过在线问卷自我报告数据,COVID-19诊断仅5例经PCR确诊。
  • 样本来自3家转诊中心,10天内完成,可能存在选择偏倚。
  • 对重症病例信息有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic disease characterised by autoimmunity and increased susceptibility to infections. COVID-19 is a systemic viral disease currently spreading as a pandemic. Little is known about the impact of COVID-19 in patients with SLE. OBJECTIVE: to acquire information on the impact of COVID-19 in SLE. METHODS: A 26-item anonymous questionnaire investigating demographics, SLE clinical features, COVID-19 diagnoses and changes in treatments and daily habits was administered to patients with SLE from three referral centres through www.surveymonkey.com over 10 days. Data from the survey were compared to those from published estimates about the general population. RESULTS: Four-hundred-seventeen patients responded to the survey. More than 60% of subjects complained of symptoms that are also associated to COVID-19. Fourteen COVID-19 diagnoses (five confirmed by polymerase chain reaction) were reported, in contrast to a 0.73% prevalence of confirmed cases in Lombardy. One hospitalisation was reported. Fever, anosmia, dry cough, a self-reported history of neuropsychiatric SLE and a recent contact with confirmed COVID-19 cases were more strongly associated with COVID-19, as were symptoms and lower compliance to behavioural preventive measures in patients' contacts. No protective effect was seen in subjects on hydroxychloroquine. CONCLUSION: COVID-19 morbidity might only moderately be increased in most patients with SLE, although limited information can be inferred on more severe cases. Hydroxychloroquine apparently seems not to confer protection to infection per se, although other beneficial roles cannot be excluded. Containment policies and behavioural preventive measures could have a major role in limiting the impact of COVID-19 in patients with SLE.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ramirez GA, Gerosa M, Beretta L, et al. COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. Semin Arthritis Rheum. 2020. PMID: 32927376. doi:10.1016/j.semarthrit.2020.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。